1 research outputs found
Mouse Bone Marrow Mesenchymal Stem Cells Inhibit Sepsis-Induced Lung Injury in Mice via Exosomal SAA1
Sepsis
is a global disease burden, and approximately 40% of cases
develop acute lung injury (ALI). Bone marrow mesenchymal stromal cells
(BMSCs) and their exosomes are widely used in treating a variety of
diseases including sepsis. As an acute phase protein, serum amyloid
A1 (SAA1) regulates inflammation and immunity. However, the role of
SAA1 in BMSCs-exosomes in septic lung injury remains to be elucidated.
Exosomes derived from serum and BMSCs were isolated by ultracentrifugation.
SAA1 was silenced or overexpressed in mouse BMSCs using lentiviral
plasmids, containing either SAA1-targeting short interfering RNAs
or SAA1 cDNA. Sepsis was induced by cecal ligation and puncture (CLP).
LPS was used to induce ALI in mice. Mouse alveolar macrophages were
isolated by flow cytometry. Levels of SAA1, endotoxin, TNF-α,
and IL-6 were measured using commercial kits. LPS internalization
was monitored by immunostaining. RT-qPCR or immunoblots were performed
to test gene and protein expressions. Serum exosomes of patients with
sepsis-induced lung injury had significantly higher levels of SAA1,
endotoxin, TNF-α, and IL-6. Overexpression of SAA1 in BMSCs
inhibited CLP- or LPS-induced lung injury and decreased CLP- or LPS-induced
endotoxin, TNF-α, and IL-6 levels. Administration of the SAA1
blocking peptide was found to partially inhibit SAA1-induced LPS internalization
by mouse alveolar macrophages and reverse the protective effect of
SAA1. In conclusion, BMSCs inhibit sepsis-induced lung injury through
exosomal SAA1. These results highlight the importance of BMSCs, exosomes,
and SAA1, which may provide novel directions for the treatment of
septic lung injury